RxDoctor Payments Data

Dwayne Platt, MD

Family Medicine · Salisbury, PANPI 1912908047

Payments from drug & device makers

$977in general payments, 2019–2025

Across 39 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$318
  • Pfizer$208
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • GSK$62
  • Amgen$42
  • AbbVie$40
  • plus $183 from 10 others

What the payments were for

  • Food & beverage$977100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$977 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$75,576
Medicare patients
208
Services billed
1,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin235$226,332
OzempicSemaglutide111$129,089
EliquisApixaban125$112,007
TrulicityDulaglutide87$88,815
XareltoRivaroxaban37$36,100
TradjentaLinagliptin43$33,270
MounjaroTirzepatide28$28,711
EntrestoSacubitril/Valsartan36$28,384
RybelsusSemaglutide26$26,660
JanuviaSitagliptin Phosphate30$22,488
Breo ElliptaFluticasone/Vilanterol35$18,226
FarxigaDapagliflozin Propanediol14$12,624
Xultophy 100-3.6Insulin Degludec/Liraglutide13$12,394
Lantus SolostarInsulin Glargine,hum.Rec.Anlog108$11,086
JentaduetoLinagliptin/Metformin Hcl11$10,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Jentadueto Xr, Spiriva Respimat$17$281,682313 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$318$168,143150 claims
PfizerEliquis$208$112,007125 claims
Johnson & JohnsonXarelto$24$36,10037 claims
MerckJanuvia, Janumet$14$30,76245 claims
NovartisEntresto$27$28,38436 claims
GSKBreo Ellipta, Trelegy Ellipta$62$26,36148 claims
AstraZenecaFarxiga$14$12,62414 claims
AbbVieSynthroid$40$4,26594 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Salisbury

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →